MAR 20, 2014 08:00 AM PDT
Biomarkers, Cognition and Cognitive Reserve in Alzheimers Disease
Presented at the Neuroscience Virtual Event
104 54 2685

Speakers:
  • Assistant Professor at the Aging and Dementia Imaging Laboratory, Department of Radiology, Mayo Clinic
    Biography
      Dr. Vemuri is an Assistant Professor at the Aging and Dementia Imaging Laboratory, Department of Radiology, Mayo Clinic Rochester. She has a Masters and Doctorate from the Department of Electrical Engineering at University of Utah, Salt Lake City with a major in Medical Imaging. She completed a fellowship with Dr. Clifford Jack at the Mayo Clinic in imaging of neurodegenerative diseases. She is a recipient of the NIH K99/R00 Pathway to Independence grant from the NIA, Alzheimers Association New Investigator grant award and was recently awarded the AFAR-GE healthcare junior investigator award for excellence in aging and imaging research. Dr. Vemuris areas of research are developing and validating biomarkers to improve the understanding and management of Alzheimers disease and related disorders and utilize biomarkers to improve our understanding of cognitive reserve i.e. the disconnect between pathology and cognitive performance in individuals.

    Abstract:

    Late onset dementia is usually a multi-factorial disease wherein cumulative pathological brain insults (of more than one pathology) results in progressive cognitive decline which ultimately leads to impairment in ones ability to function at work and/or perform usual activities/tasks. Until recently, postmortem examination has been the only way to accurately determine the underlying pathology that led to dementia. However with the recent emergence of advanced imaging technologies, imaging indicators of disease that closely reflect the underlying pathology have been found to be very useful in aiding the prediction of the underlying dementia pathology. In the first part of the talk, we will discuss how different biomarkers could be used to measure different aspects of Alzheimers disease (AD) pathology, a leading cause of dementia and how they can aid in answering several important questions about the disease processes. In the second part of the talk, we will talk about the concept of cognitive reserve (CR) and how it may aid in delaying the onset of dementia. CR is the term often used to explain why about 30% of cognitively normal subjects with AD pathology do not show any cognitive symptoms. Our recent studies have shown that even though CR does not appear to impact the degree of pathological deposition in the brain but it has an independent effect on cognitive performance wherein subjects with higher reserve have a greater capacity to cope with pathological insults and these individual differences in reserve mechanisms help explain why cognitive decline may be initiated at different times in relation to the onset of pathology. Learning Objectives: 1) Discuss how the role of biomarkers in Alzheimers disease 2) Describe the concept of cognitive reserve and explain the mechanisms through which it delays the onset of Alzheimers disease


    Show Resources
    Loading Comments...